Goldman Sachs
SKYE icon

Goldman Sachs’s Skye Bioscience SKYE Stock Holding History

Goldman Sachs’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-73,126
Closed -$287K – 6884
2025
Q3 		$287K Sell
73,126
-708
-1% -$2.67K ﹤0.01% 5777
2025
Q2 		$309K Buy
73,834
+30,343
+70% +$62.8K ﹤0.01% 5428
2025
Q1 		$69.2K Sell
43,491
-27,588
-39% -$75.3K ﹤0.01% 5841
2024
Q4 		$201K Buy
71,079
+23,279
+49% +$97.3K ﹤0.01% 5646
2024
Q3 		$187K Buy
+47,800
New +$268K ﹤0.01% 5477

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Goldman Sachs's SKYE Position: Q4 2025 in Review

Goldman Sachs sold out of Skye Bioscience (SKYE) in Q4 2025, closing a stake of 73,126 shares — an estimated $287K sold.

Goldman Sachs first reported a position in SKYE in Q3 2024 and held it in 5 quarters. The position peaked at $309K in Q2 2025. 50 funds tracked by Wall St. Rank hold SKYE as of Q4 2025.

  • Goldman Sachs reported no remaining Skye Bioscience position as of Q4 2025 after selling out during the quarter.
  • Goldman Sachs sold 73,126 Skye Bioscience shares in Q4 2025, an estimated $287K.
  • Goldman Sachs first reported a position in Skye Bioscience in Q3 2024 and held it in 5 quarters.
  • Goldman Sachs's Skye Bioscience position peaked at $309K in Q2 2025.
  • 50 funds tracked by Wall St. Rank held Skye Bioscience as of Q4 2025.

Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.